Dr. Pusztai on Challenges With Neoadjuvant HER2 Therapy

Lajos Pusztai, MD
Published: Tuesday, Nov 28, 2017



Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Pusztai says that one of the biggest challenges is understanding which patient needs what treatment—pertuzumab (Perjeta), trastuzumab (Herceptin), or chemotherapy.

Additionally, there are patients who are able to achieve a good response with fewer treatments, and those patients need to be selected, Pusztai adds.
 
SELECTED
LANGUAGE


Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Pusztai says that one of the biggest challenges is understanding which patient needs what treatment—pertuzumab (Perjeta), trastuzumab (Herceptin), or chemotherapy.

Additionally, there are patients who are able to achieve a good response with fewer treatments, and those patients need to be selected, Pusztai adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x